In Soite, vac­ci­na­tions with a third dose of coro­n­avirus vac­cine will start this week for peo­ple aged 60 and old­er, for peo­ple who belong to a risk group and for clients liv­ing at ser­vice hous­ing units

The Nation­al Insti­tute for Health and Wel­fare THL has instruct­ed the regions to start admin­is­ter­ing a third dose of the coro­n­avirus vac­cine for the fol­low­ing tar­get groups: all those over 60 years of age, res­i­dents at insti­tu­tions and nurs­ing homes regard­less of age, and those over 12 years of age who belong to risk group 1 or 2. The admin­is­tra­tion of a third dose of vac­cine to these tar­get groups will begin in Soite this week (week 43). The third dose of the vac­cine can be giv­en when at least 6 months have passed since the sec­ond vac­cine dose.

For res­i­dents at insti­tu­tions and care homes, the third dose will be giv­en at Soite’s ser­vice hous­ing units. The vac­ci­na­tions at Soite’s ser­vice hous­ing units will begin week 43.

All per­sons over 60 years of age and all per­sons over 12 years of age in risk groups 1 and 2 can vis­it Soite’s vac­ci­na­tion sites for a third coro­n­avirus vac­ci­na­tion if at least 6 months have passed since they received their sec­ond dose. By med­ical risk group, we mean groups 1 and 2 in the vac­ci­na­tion schedule.

Group 1: 12–60-year-old per­sons who have an ill­ness or con­di­tion that is high­ly pre­dis­pos­ing to severe coro­n­avirus disease.

  • Organ transplant or stem cell transplant
  • People undergoing active cancer treatment
  • Severe disorders of the immune system
  • Severe chronic renal disease
  • Severe chronic pulmonary disease
  • Type 2 diabetes with medication
  • Down syndrome

Group 2: 12–60-year-old per­sons who have an ill­ness or con­di­tion that is high­ly pre­dis­pos­ing to severe coro­n­avirus disease.

  • Asthma that requires continuous medication
  • A severe heart disease, including heart insufficiency (but not just hypertension)
  • A neurological disease or condition that affects respiration
  • Persons undergoing immunosuppressive drug therapy for an autoimmune disease
  • Severe chronic renal disease
  • Type 1 diabetes or adrenal insufficiency
  • Sleep apnea
  • A psychotic disease
  • Morbid obesity (body mass index over 40)

Addi­tion­al infor­ma­tion about risk groups 1 and 2 on the institute’s web page (in Finnish).

The third dose of the vac­cine is pri­mar­i­ly giv­en using the same vac­cine as was used for the sec­ond dose, unless there is a med­ical hin­drance for this. Addi­tion­al infor­ma­tion in the Institute’s mes­sage (in Finnish).

In addi­tion, the THL rec­om­mends that the elder­ly and those in a med­ical risk group for seri­ous coro­n­avirus dis­ease who have been diag­nosed with coro­n­avirus dis­ease and have received one dose of coro­n­avirus vac­cine should receive a sec­ond dose of the vac­cine as a boost­er. A sec­ond dose of vac­cine can be giv­en to them at the ear­li­est six months after either the coro­n­avirus infec­tion or the lat­est dose of vac­cine, whichev­er is more recent.

The third vac­cine dose is giv­en at Soite’s vac­ci­na­tion sites

The third dose of the vac­cine can be giv­en when at least 6 months have passed since the sec­ond vac­cine dose. The infor­ma­tion is checked at the vac­ci­na­tion site and if less than 6 months have passed since the sec­ond vac­ci­na­tion, a third vac­cine dose can­not yet be given.

The third dose is giv­en at Soite’s vac­ci­na­tion sites. You can get vac­ci­nat­ed dur­ing a pre-booked appoint­ment or by vis­it­ing an appoint­ment-free walk-in vaccination.

On vac­ci­na­tion days with­out appoint­ment book­ing, you can come to get your coro­n­avirus vac­ci­na­tion when it suits you best. Addi­tion­al infor­ma­tion and the timetable for the walk-in days can be found on Soite’s coro­n­avirus web­site:

An appoint­ment for a coro­n­avirus vac­ci­na­tion may be booked online on or via the sec­re­tary of the vac­ci­na­tion cen­tral, phone 040 804 2821 Mon­day-Fri­day 12 noon — 3 pm or by phone via your local health cen­tre. The elec­tron­ic appoint­ment book­ing for the third dose will open this week.

Recip­i­ents of the third vac­cine dose may, if they wish, receive the influen­za vac­cine at the same vis­it, so that they do not con­stant­ly have to go get vac­ci­nat­ed. Influen­za vac­ci­na­tions for the rest of the pop­u­la­tion will begin in mid-Novem­ber, and we will inform you more about this in Soite’s chan­nels in the near future.


For the third dose, we will uti­lize Bion­tech-Pfiz­er’s Comir­naty vac­cine and Mod­er­nan’s Spike­vax vac­cine. It is rec­om­mend­ed that the third dose be giv­en using pri­mar­i­ly the same prod­uct that was used for the sec­ond vac­cine dose, but if nec­es­sary, anoth­er prod­uct may be offered.

How­ev­er, when Moderna’s Spike­vax is giv­en as a third dose, only half a dose is used. In the vac­cine man­u­fac­tur­er’s stud­ies, half a dose has been used as a boost­er dose and a very good vac­cine response has been achieved with this dosage. With a low­er dose of Spike­vax, the like­li­hood of side effects is also lower.

Comir­naty or half a dose of Spike­vax is also rec­om­mend­ed for the third vac­cine dose for per­sons who have been vac­ci­nat­ed with a short inter­val. For severe­ly immuno­com­pro­mised patients, a full dose of Spike­vax may still be giv­en as a third dose.

If the per­son who is to be vac­ci­nat­ed can­not be giv­en an mRNA vac­cine because of an aller­gy, AstraZeneca or Janssen can be used.


Social Media